Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | DRD3 | P35462 | 4/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280757 | 1.00 | MAPT (0.63) | MAPTFUCA1DRD2DRD3GBA1 | |
| SCHEMBL2282579 | 1.00 | MAPT (0.63) | MAPTFUCA1DRD2DRD3GBA1 | |
| SCHEMBL5744287 | 0.91 | MAPT (0.54) | MAPTFUCA1DRD2DRD3GBA1 | |
| SCHEMBL17426076 | 0.89 | MAPT (0.59) | MAPTFUCA1DRD2DRD3GBA1 | |
| SCHEMBL17426073 | 0.89 | MAPT (0.59) | MAPTFUCA1DRD2DRD3GBA1 | |
| SCHEMBL16024846 | 0.89 | MAPT (0.59) | MAPTFUCA1DRD2DRD3GBA1 | |
| SCHEMBL19034817 | 0.82 | MAPT (0.52) | MAPTFUCA1DRD2DRD3GBA1 | |
| SCHEMBL18479257 | 0.82 | GBA1 (0.60) | MAPTFUCA1GBA1 | |
| SCHEMBL3609150 | 0.82 | GBA1 (0.60) | MAPTFUCA1GBA1 | |
| SCHEMBL5744903 | 0.82 | MAPT (0.46) | MAPTDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981909-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20160046574-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| US-20140038943-A1 | SEROTONIN RECEPTOR MODULATOR | JANSSEN PHARMACEUTICA NV (US) | 2014-02-06 | — | — | US | disclosed |
| US-8642583-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-04 | — | — | US | disclosed |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038943-A1 | SEROTONIN RECEPTOR MODULATOR | HTR2C, HTR2A, HTR1A | MAPT 2490/4885FUCA1 3703/4885DRD2 168/4885 |
| US-20160046574-A1 | SEROTONIN RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | MAPT 2411/4885FUCA1 3645/4885DRD2 172/4885 |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR2C | MAPT 2509/4885FUCA1 2377/4885DRD2 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.